A2780 Cell Line
Invented at NIH
Catalogue Number | 152707 |
Antigen/Gene or Protein Targets | Adriamycin resistance |
Parental Line | A2780 |
Host | Human |
Tissue | Ovary |
Disease Keywords | Carcinoma |
Model | Tumour line |
Relevance | The adriamycin-resistant cell line A2780ADR has been developed by exposure of the parent A2780 cell line (catalogue no. 152706) to adriamycin. A2780ADR is cross-resistant to melphalan and vinblastine. To retain resistance adriamycin has to be added to the media. The cells grow as a monolayer and in suspension in spinner cultures and are tumourigenic in immune deficient mice. Together with the cisplatin-resistant variant A2780cis (catalogue no. 152708_ these lines only differ in their exposure to a single drug and should facilitate the search for molecular changes responsible for the expression of pleiotropic drug resistance in human ovarian cancer. |
Production Details | Split sub-confluent cultures (70-80%) 1:5 to 1:10 i.e. seeding at 5x1,000 to 2x10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. Recommendation: culture cells without drug after resuscitation until growth has been fully established. |
Conditional | No |
Research Area | Cancer, Drug Discovery & Development |
Growth/Phenotype Keywords | Adherent |
Recommended Growing Conditions | RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS); treatment with 10E-7 M adriamycin at least once a week. |
Notes |
STR-PCR Data: Amelogenin: X CSF1PO: 10,11 D13S317: 13 D16S539: 11,14 D5S818: 11,12 D7S820: 10 THO1: 6 TPOX: 8,9 vWA: 15,16 |
Cellosaurus ID | CVCL_1941 |
Beaufort et al. 2014. PLoS One. 9(9):e103988. PMID: 25230021.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Europe PMC ID: 25230021
Hamilton et al. 1984. Semin Oncol. 11(3):285-98. PMID: 6385258.
Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches.
Europe PMC ID: 6385258
Beaufort et al. 2014. PLoS One. 9(9):e103988. PMID: 25230021.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Hamilton et al. 1984. Semin Oncol. 11(3):285-98. PMID: 6385258.
Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches.